Drug intelligence / Profile preview

hexavalent group b streptococcus conjugate vaccine

Development stage
Phase 1
Lead developer
Pfizer
Modality
Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Hexavalent group B streptococcus conjugate vaccine is a multivalent vaccine candidate being developed by Ningbo Rong'an Biological Pharmaceutical, a subsidiary of AIM Vaccine. It is designed to prevent Group B Streptococcus (GBS) infections, which are a leading cause of neonatal sepsis, pneumonia, and meningitis. The vaccine utilizes a conjugate technology platform, linking capsular polysaccharides from six common GBS serotypes to a carrier protein to enhance immunogenicity and induce a T-cell dependent immune response. The primary development strategy involves maternal immunization to provide passive protection to infants through the transplacental transfer of protective antibodies.

Other names
6-valent GBS conjugate vaccinehexavalent GBS vaccine
02

Targets

GBS CPS (Group B Streptococcus capsular polysaccharide)

Beyond the preview

Go deeper on hexavalent group b streptococcus conjugate vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hexavalent group b streptococcus conjugate vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call